The latest biotech news

News and Trends 17 Jan 2023

Poolbeg expands POLB 001 into oncology

Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is a strain agnostic, small molecule immunomodulator being studied to address the unmet medical need for a treatment for severe influenza. While investigating the role of cytokine release syndrome (CRS) in severe influenza, Poolbeg discovered data specific to the overt immune […]

January 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

Multus Biotechnology closes $9.5M funding to bring cultivated meat closer to price parity

Multus Biotechnology Limited, a U.K.-based start-up creating ingredients for the affordable scale-up of cellular agriculture, has completed a £7.9 million ($9.5 million) funding round led by Mandi Ventures. Other investors include SOSV, Big Idea Ventures and SynBioVen, alongside Asahi Kasei, a global company that contributes to a sustainable society by tackling evolving challenges in materials, […]

January 17, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate

EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, says the first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax AK in lung and kidney cancer patients. The aim of the trial is to assess the toxicity and efficacy […]

January 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

TTP spinout Cellular Origins to focus on cell and gene therapies

TTP plc, a technology and product development company, has announced the launch of Cellular Origins. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellular Origins’ proprietary technology addresses the current barriers associated with the manufacture of advanced therapies that are in late-stage development, enabling […]

January 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

Beyond Biotech podcast 29: Janssen, Knowledge Gate

This week, our guests are Viktoriya Vasilenko, Knowledge Gate co-founder and CEO; and Avery Ince, vice president, medical affairs, cardiovascular & metabolism at Janssen Scientific Affairs, LLC. Study confirms benefit of XARELTO (rivaroxaban) for secondary prevention of venous thromboembolism in cancer patients The Janssen Pharmaceutical Companies of Johnson & Johnson has revealed observational data from […]

January 12, 2023

News and Trends 12 Jan 2023

Anticancer drugs could lead to new sepsis treatment

Researchers at the Instituto Gulbenkian de Ciência (IGC) in Oeiras, Portugal, say because anti-cancer drugs limit inflammation, they could be a potential treatment for sepsis. The study, published in eLife, reveals that the class of drugs used in cancer treatment limit the unrestrained production of inflammatory mediators by the immune system. The discovery positions these […]

January 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases

The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has issued a call for multinational research on large scale analysis of OMICS data for drug-target finding in neurodegenerative diseases. Neurodegenerative diseases are debilitating and largely untreatable conditions that are strongly linked with age. Worldwide, there are estimated to be 50 million people with Alzheimer’s […]

January 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

Breast cancer most studied disease area in 2022

Phesi, a global provider of patient-centric data analytics, has released the results of its global analysis of all clinical trials conducted in 2022. The report, which analyzed 80,917 trial records, reveals that breast cancer retained its position as the most-studied disease area, followed by COVID-19. Three of the top five most-studied disease areas fell within oncology, […]

January 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

Collaboration to boost pandemic preparedness, structure-based drug discovery and vaccine design

A new Memorandum of Understanding (MoU) to facilitate collaboration in the field of pandemic preparedness and to promote further cooperation between the University of Oxford and Diamond Light Source has been announced. The University of Oxford and Diamond Light Source already have many links but now intend to develop their collaborative work to address multiple […]

January 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

Team wins $149M contract for National Institute of Neurological Disorders and Stroke

A team consisting of Battelle, AmplifyBio and Andelyn Biosciences has won a seat on an eight-year, $149 million indefinite delivery, indefinite quantity (IDIQ) contract vehicle for the National Institute of Neurological Disorders and Stroke in the U.S. As one of the prime contractors on the multi-award IDIQ, the team will provide manufacturing and nonclinical support […]

January 12, 2023 - 3 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 12 Jan 2023

Ajinomoto and Exelixis to discover and develop novel ADCs to treat cancer

Ajinomoto Co., Inc. has signed a license agreement with Exelixis, Inc. to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of some of Exelixis’ antibody-drug conjugate (ADC) programs. Exelixis is an oncology-focused biotechnology company looking to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Utilizing its […]

January 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

Renexxion goes to FDA with cystic fibrosis drug

Renexxion Ireland Limited has opened an investigational new drug (IND) application with the U.S Food and Drug Administration (FDA) for naronapride for the treatment of GI motility disorders in patients with cystic fibrosis (CF). This is a first step towards conducting clinical trials of the drug candidate in CF patients. Naronapride, post approval, could be […]

January 11, 2023 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Poolbeg expands POLB 001 into oncology

Multus Biotechnology closes $9.5M funding to bring cultivated meat closer to price parity

EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate

TTP spinout Cellular Origins to focus on cell and gene therapies

Beyond Biotech podcast 29: Janssen, Knowledge Gate

Anticancer drugs could lead to new sepsis treatment

JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases

Breast cancer most studied disease area in 2022

Collaboration to boost pandemic preparedness, structure-based drug discovery and vaccine design

Team wins $149M contract for National Institute of Neurological Disorders and Stroke

Ajinomoto and Exelixis to discover and develop novel ADCs to treat cancer

Renexxion goes to FDA with cystic fibrosis drug

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!